Joel Ackerman - Insider Trading Tracker

Introduction

This page provides a comprehensive analysis of the known insider trading history of Joel Ackerman. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

Companies with Reported Insider Positions

The SEC filings indicate Joel Ackerman has reported holdings or trades in the following companies:

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Joel Ackerman. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CSBR / Champions Oncology, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CSBR / Champions Oncology, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2016-10-18	CSBR	ACKERMAN JOEL	1,000	1.6977	1,000	1.6977	1,698	105	4.75	3,053	179.91
2016-10-18	CSBR	ACKERMAN JOEL	201	1.6940	201	1.6940	340
2016-10-18	CSBR	ACKERMAN JOEL	381	1.6900	381	1.6900	644
2016-10-18	CSBR	ACKERMAN JOEL	418	1.7000	418	1.7000	711
2016-10-14	CSBR	ACKERMAN JOEL	1,000	1.6581	1,000	1.6581	1,658
2016-10-14	CSBR	ACKERMAN JOEL	300	1.6500	300	1.6500	495
2016-10-13	CSBR	ACKERMAN JOEL	500	1.6844	500	1.6844	842
2016-10-13	CSBR	ACKERMAN JOEL	500	1.6890	500	1.6890	844
2016-10-13	CSBR	ACKERMAN JOEL	1,000	1.6700	1,000	1.6700	1,670
2016-10-13	CSBR	ACKERMAN JOEL	1,000	1.6700	1,000	1.6700	1,670
2016-10-13	CSBR	ACKERMAN JOEL	1,000	1.6766	1,000	1.6766	1,677
2016-10-13	CSBR	ACKERMAN JOEL	1,000	1.6790	1,000	1.6790	1,679
2016-10-13	CSBR	ACKERMAN JOEL	1,000	1.6700	1,000	1.6700	1,670
2016-10-07	CSBR	ACKERMAN JOEL	5,000	1.6400	5,000	1.6400	8,200
2016-10-06	CSBR	ACKERMAN JOEL	1,000	1.6108	1,000	1.6108	1,611
2016-10-06	CSBR	ACKERMAN JOEL	702	1.6200	702	1.6200	1,137
2016-10-06	CSBR	ACKERMAN JOEL	1,500	1.6143	1,500	1.6143	2,421
2016-09-23	CSBR	ACKERMAN JOEL	33	1.6500	33	1.6500	54
2016-09-21	CSBR	ACKERMAN JOEL	1,000	1.7000	1,000	1.7000	1,700
2016-09-21	CSBR	ACKERMAN JOEL	1,000	1.7287	1,000	1.7287	1,729
2016-09-20	CSBR	ACKERMAN JOEL	1,000	1.6274	1,000	1.6274	1,627
2016-09-20	CSBR	ACKERMAN JOEL	1,000	1.6399	1,000	1.6399	1,640
2016-09-20	CSBR	ACKERMAN JOEL	1,000	1.6277	1,000	1.6277	1,628
2015-03-11	CSBR	ACKERMAN JOEL	2,710,526	0.0000	225,877	0.0000	0
2013-01-28	CSBR	ACKERMAN JOEL	500,000	0.5000	41,667	6.0000	250,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Sales CSBR / Champions Oncology, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CSBR / Champions Oncology, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
2018-10-01	CSBR	ACKERMAN JOEL	22,535	17.0200	22,535	17.0200	383,546	333	5.4	-261,856	-68.27

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Trading History

This table shows the complete list of insider trades made by Joel Ackerman as disclosed to the Securities Exchange Commission (SEC).